• FDA approves Nulibry to reduce risk of death caused by rare genetic, metabolic disorder

    1 month ago - By News Medical

    Today, the U.S. Food and Drug Administration approved Nulibry for injection to reduce the risk of death due to Molybdenum Cofactor Deficiency Type A, a rare, genetic, metabolic disorder that typically presents in the first few days of life, causing intractable seizures, brain injury and death.
    Read more ...